

COPY

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

FEB 03 2005

Application No. : 09/438,365  
Applicant: : Chu et al.  
Filed: : November 12, 1999  
Examiner: : Epps, J.  
For: New Transfection Reagents.

Confirmation No.: 9217

Group Art Unit: 1635

Docket No. : 61-03  
Customer No. : 23713

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 EV 569 066 518 US	
On 2/3/05	Lea Murray

BEST AVAILABLE COPY

## ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statement filed February 3, 2004, the Examiner is respectfully requested to consider the additional references, copies enclosed, which may qualify as prior art.

Applicant would also like to draw the Examiner's attention to commonly-owned, copending U.S. applications 10/755,082, filed January 9, 2004; and 10/865,538, filed June 9, 2004, which are not listed on the PTO-1449 form. Pursuant to the Waiver of the Copy Requirement in 37 C.F.R. 1.98 for Cited Pending U.S. Patent Applications signed on September 21, 2004, and published on [www.uspto.gov](http://www.uspto.gov) on September 24, 2004, copies of pending U.S. applications that are available in the Image File Wrapper system are not submitted, but will be provided on request. All of the above commonly-owned, pending U.S. applications are available in the Image File Wrapper system.


The enclosed references are cited in a spirit of forthrightness and cooperation to enable the applicants to obtain that measure of protection for the invention to which

COPY

there is entitlement. However, no representation is made that the provided art actually qualifies as prior art under the patent statute, and provision of references is not an admission that all provided references are prior art. No representation is made that applicants know of the best art.

An electronic filing of the U.S. Patent references is being made concurrently with this filing. Authorization for payment of the fee of \$180 through deposit account 07-1969 is made with the electronic filing. Therefore, no fee is believed to be due with this submission.

Respectfully submitted,

  
Sally A. Sullivan  
Reg. No. 32,064

GREENLEE, WINNER AND SULLIVAN, P.C.  
5370 Manhattan Circle, Suite 201; Boulder, CO 80303  
Telephone: (303) 499-8080; Facsimile: (303) 499-8089  
Attorney Docket No. 61-03  
Date: February 3, 2005

COPY

FEB 03 2005  
Sheet 1 of 1

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Substitute for form 1449/PTO, based on PTO/SB/08A and 08B	Application Number	09/438,365
		Filing Date	November 12, 1999
		First Named Inventor	Chu et al.
		Art Unit	1635
		Examiner Name	Epps, J.
		Attorney Docket Number	61-03

## U.S. PATENT DOCUMENTS

Examiner Initial*	Cite No. <sup>1</sup>	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. <sup>1</sup>	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T <sup>2</sup>
		WO04/083342	07/29/04	Dalby		
		WO04/105697	12/09/04	Gebeyehu		

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. <sup>1</sup>	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Asokan, A. and Cho, M.J. (2004), "Cytosolic Delivery of Macromolecules. 3. Synthesis and Characterization of Acid-Sensitive Bis-Detergents," Bioconj. Chem. 15:1166-1173	
		Banerjee, R. et al. (1999), "Novel Series of Non-Glycerol-Based Cationic Transfection Lipids for Use in Liposomal Gene Delivery," J. Med. Chem. 42:4292-4299	
		Bennett, M.J. et al. (1997), "Cationic Lipid-Mediated Gene Delivery to Murine Lung: Correlation of Lipid Hydration with in Vivo Transfection Activity," J. Med. Chem. 40:4069-4078	
		Bergeron, R.J. et al. (1996), "Metabolically Programmed Polyamine Analogue Antidiarrheals," J. Med. Chem. 39:2461-2471	
		Mack, K.D. (Feb 1994), "Cationic lipid enhances in vitro receptor-mediated transfection," Am. J. Med. Sci. 307:138-143	
		Mazur, W. et al. (Feb 1993), "Direct Gene Transfer into the Coronary Arteries of Intact Animals via Infusion Balloon Catheters: Comparison of Canine and Procine Model Systems," J. Am. Coll. Cardiol. 21(2):186A	
		Singh, R.S. et al. (2002), "Anchor Dependency for Non-Glycerol Based Cationic Lipofectins: Mixed Bag of Regular and Anomalous Transfection Profiles," Chem. Eur. J. 8:900-909	
		Trubetskoy, V.S. et al. (Jul 1992), "Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells," Biochim. Biophys. Acta. 1131:311-313	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here or "x" if English language Translation is attached.